Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

v3.19.3
Accrued Expenses and Other Current Liabilities
9 Months Ended
Sep. 30, 2019
Payables And Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities

(9)

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

 

 

 

September 30,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Clinical trial and related costs

 

$

101

 

 

$

683

 

Professional and consulting fees

 

 

1,012

 

 

 

671

 

Payroll and related costs

 

 

1,753

 

 

 

2,172

 

Accrued restructuring costs

 

 

1,386

 

 

 

 

Property, plant and equipment

 

 

 

 

 

278

 

Pre-commercialization scale-up costs

 

 

 

 

 

4,445

 

Other research and development costs

 

 

136

 

 

 

678

 

Other

 

 

112

 

 

 

846

 

 

 

$

4,500

 

 

$

9,773

 

 

After the receipt of the second CRL, the Company incurred approximately $7,200 in restructuring costs (all which was incurred in the first half of 2019), of which $1,386 remains accrued and unpaid as of September 30, 2019.